Back Back
ASH 2024 Preview
An Expert’s Guide to ASH 2024: Preview of the Top Abstracts

Released: December 05, 2024

Expiration: December 04, 2025

Jeremy S. Abramson
Jeremy S. Abramson, MD, MMSc
Catherine M. Broome
Catherine M. Broome, MD
Jonathon B. Cohen
Jonathon B. Cohen, MD, MS
Corey Cutler
Corey Cutler, MD, MPH
Courtney DiNardo
Courtney DiNardo, MD, MSCE
Rami Komrokji
Rami Komrokji, MD
Sagar Lonial
Sagar Lonial, MD, FACP
Noopur Raje
Noopur Raje, MD
Eytan M. Stein
Eytan M. Stein, MD
Amer Zeidan
Amer Zeidan, MBBS, MHS
Activity Information

Activity

Progress
1
Course Completed
Continue

The 2024 American Society of Hematology (ASH) Annual Meeting and Exposition will feature significant results from numerous clinical studies in varied hematologic diseases. As part of CCO’s Independent Conference Coverage of ASH 2024, experts have identified a list of anticipated abstracts. Remember to check the CCO website often as the meeting unfolds for downloadable slidesets summarizing the data from these studies and more. After the meeting, join us for our live, interactive “Conference to Clinic” webinars on Saturday, January 18, as experts discuss some of the most important data presented during ASH 2024 and how they plan to change their practice, as well as answer your questions.

Top Picks: Acute Leukemias and Chronic Myeloid Leukemia

For leukemias, Courtney D. DiNardo, MD, and Eytan Stein, MD, identified the following as top abstracts of studies to watch.

Acute leukemias

  • Survival outcomes from an expanded and updated cohort of newly diagnosed patients with acute myeloid leukemia (AML) in the phase II study of cladribine and low-dose cytarabine and venetoclax induction therapy followed by consolidation therapy with alternating azacitidine and venetoclax with cladribine, and low-dose cytarabine and venetoclax (Abstract 56): Data to be presented at the meeting suggest that this increasingly recognized “intermediate intensity” regimen may have a particularly strong impact in older patients with signaling mutations or monocytic disease where the use of a hypomethylating agent plus venetoclax is suboptimal.
  • AUGMENT-101: Updated efficacy and safety results from a longer follow-up of the phase II study of the menin inhibitor revumenib in patients with relapsed/refractory acute leukemia harboring KMT2Ar rearrangements (Abstract 211).
  • SAVE: Efficacy and safety results from the phase I/II study of an all-oral combination of revumenib, decitabine/cedazuridine, and venetoclax for patients with relapsed/refractory AML (Abstract 216): Data to be presented at the meeting highlight the potential role of the combination of revumenib with venetoclax-based regimens.
  • GIMEMA ALL2820: Updated efficacy and safety results from a phase III study of ponatinib followed by blinatumomab for adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL) (Abstract 835): Data to be presented at the meeting indicate high levels of hematologic remission with the combination of ponatinib and blinatumomab in a large number of patients with ALL.
  • CALGB 10603/RATIFY: Ten-year follow-up efficacy and safety results from the phase III study of midostaurin vs placebo in combination with intensive chemotherapy for newly diagnosed patients aged 18-60 years with FLT3-mutant AML (Abstract 218).

Chronic myeloid leukemia

  • ASC4FIRST: Updated efficacy, safety and tolerability results from the pivotal phase III trial of asciminib vs all standard-of-care tyrosine kinase inhibitors in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) (Abstract 475): Data to be presented at the meeting reinforce that asciminib is associated with a low adverse effects profile and elicits excellent early response rates, including a superior 1-year major molecular response rate.
  • ASCEND-CML: Updated efficacy and safety outcomes for newly diagnosed patients with CML-CP from the phase II trial of treatment with asciminib monotherapy or, for patients failing to achieve treatment response milestones, in combination with imatinib, dasatinib, or nilotinib (Abstract 476).

Top Picks: Lymphomas
For lymphomas, Jeremy S. Abramson, MD, MMSc, and Jonathon Cohen, MD, identified the following as key abstracts being presented.

Follicular lymphoma

  • inMIND: Data from a randomized phase III trial of tafasitamab vs placebo for patients with relapsed/refractory CD19/CD20+ follicular lymphoma after ≥1 prior systemic therapy, including an anti-CD20 monoclonal antibody (Abstract LBA-1).
  • Mithic-FL1: Primary analysis data from a phase II trial of mosunetuzumab for newly diagnosed, high-burden CD20+ follicular lymphoma (Abstract 340).
  • A phase I study of AZD0486 (a CD19 x CD3 bispecific antibody) for patients with relapsed/refractory CD19+ follicular lymphoma with ≥2 prior lines of therapy (Abstract 341).

Mantle cell lymphoma

  • EA4151: Interim data from a phase III trial in patients with mantle cell lymphoma (MCL) in first remission after induction therapy; those with complete remission with undetectable measurable residual disease (MRD) were randomized to autologous hematopoietic cell transplantation (auto-HCT) plus maintenance rituximab vs maintenance rituximab alone, whereas those with MRD-positive or MRD-indeterminate complete remission received auto-HCT plus maintenance rituximab (Abstract LBA-6).
  • ALTAMIRA: Data from a phase II study of acalabrutinib plus rituximab for patients aged 60 years or older with previously untreated MCL; this study included MRD-guided treatment duration for select patients (Abstract 747).

Chronic lymphocytic leukemia

  • AMPLIFY: Interim data from a randomized phase III trial of fixed-duration acalabrutinib plus venetoclax with or without obinutuzumab vs chemoimmunotherapy as first-line therapy for patients with chronic lymphocytic leukemia (CLL) (Abstract 1009).
  • BRUIN CLL-321: Interim data from a randomized phase III trial of pirtobrutinib vs idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory CLL/small lymphocytic lymphoma previously treated with a covalent Bruton tyrosine kinase (BTK) inhibitor (Abstract 886).

Top Picks: Multiple Myeloma

For multiple myeloma (MM), Sagar Lonial, MD, and Noopur Raje, MD, identified the following as key abstracts with novel treatment approaches to watch:

  • AQUILA: A randomized phase III trial comparing daratumumab vs active monitoring for patients with intermediate-risk or high-risk smoldering MM (Abstract 773): These highly anticipated study results will provide additional information on the potential benefit of early intervention for a subset of patients with smoldering MM, with the goal of preventing CRAB symptoms (calcium elevation, renal failure, anemia, and bone disease) for patients with a high risk of progression to active MM within 2 years.
  • IFM2017-03: A randomized phase III trial of lenalidomide/dexamethasone compared with a dexamethasone-sparing regimen including daratumumab and lenalidomide in patients with newly diagnosed MM who are older than 65 years of age and have an Eastern Cooperative Oncology Group proxy frailty score of ≥2 (Abstract 774): The data suggest that daratumumab/lenalidomide with only 2 cycles of dexamethasone results in a significant benefit compared with standard lenalidomide/dexamethasone in frail patients.
  • MajesTEC-4/EMN30: A 3-arm, randomized phase III trial comparing time-limited maintenance therapy with teclistamab/lenalidomide, teclistamab alone, or lenalidomide alone after autologous stem cell transplantation and standard induction therapy: At ASH 2024, the data from the safety run-in cohorts with different teclistamab dosing will be presented (Abstract 494).
  • DREAMM-7: A randomized phase III trial has evaluated the efficacy and safety of belantamab mafodotin with bortezomib/dexamethasone vs daratumumab with bortezomib/dexamethasone (Abstract 772). Data presented at ASH 2024 will provide information on a suggested overall survival benefit in addition to longer follow-up for the statistically significant progression-free survival benefit.
  • Updated data from a phase I study exploring the efficacy and safety of GPRC5D-targeted CAR T-cell therapy, BMS-986393, in patients with relapsed/refractory MM after ≥3 prior regimens including a proteasome inhibitor, an immunomodulatory agent, and anti-CD38 therapy (prior BCMA-directed therapies, including CAR T-cells, were allowed) (Abstract 922).
  • Updated results from the phase I/II CC-92480-MM-002 trial of the novel CELMoD mezigdomide in combination with bortezomib/dexamethasone or carfilzomib/dexamethasone in patients with relapsed/refractory MM after prior treatment regimens including lenalidomide, and documented progressive disease during or after the last MM therapy (Abstract 1025).

Top Picks: Myelodysplastic Syndromes/Myeloproliferative Neoplasms

For myelodysplastic syndromes (MDS)/myeloproliferative neoplasms (MPN), Rami Komrojki, MD, and Amer Zeidan, MBBS, MHS, identified the following as abstracts of key studies to watch:

  • EPO-Pretar: This European, open-label, randomized phase III trial evaluated early vs delayed onset of erythropoiesis-stimulating agent (ESA) in non–transfusion-dependent, lower-risk patients with MDS and anemia (Abstract 349).
  • GFM Combola: This phase I/II trial investigated the combination of ESA and the erythroid maturation agent luspatercept in patients with low-risk MDS without ring sideroblasts who failed to respond to ESA (Abstract 351).
  • IMerge: A pooled data analysis of the effect of prior treatments on the clinical activity of imetelstat, a telomerase inhibitor, in red blood cell transfusion–dependent patients with ESA-relapsed/refractory/ineligible, lower-risk MDS (Abstract 352).
  • A multicenter, randomized controlled trial with decitabine plus all-trans retinoic acid vs decitabine monotherapy for patients with MDS and excess blasts (Abstract 663).
  • BOREAS: A global, multicenter, randomized phase III study with navtemadlin, an MDM2 inhibitor, vs best available therapy in patients with JAK inhibitor–relapsed/refractory myelofibrosis (Abstract 1000).

The following abstract is also a study to watch:

  • COMMANDS: This study involved a long-term analysis of transfusion independence and cumulative response in ESA-naive patients with very low–risk, low-risk, or intermediate-risk MDS treated with luspatercept vs epoetin alfa (Abstract 350).

Top Picks: Nonmalignant Hematologic Conditions

For nonmalignant hematologic conditions, Catherine Broome, MD, and Corey Cutler, MD, MPH, identified the following as key abstracts to watch:

  • LUNA 3: A placebo-controlled, parallel-group, multicenter phase III study that evaluated the efficacy and safety of the oral BTK inhibitor rilzabrutinib in adults with previously treated immune thrombocytopenia (ITP) (Abstract 5).
  • Another study highlighted ELA026, a signal regulatory protein-α/β1/γ-targeted monoclonal antibody that was suggested to rapidly control inflammation and improve 2-month survival in treatment-naive, malignancy-associated hemophagocytic lymphohistiocytosis (Abstract 805).
  • Updated results from a multicenter phase Ib/IIa trial with the JAK/Rock inhibitor, rovadicitinib, for patients with glucocorticoid-refractory or -dependent chronic graft-vs-host disease (cGVHD) (Abstract 97).
  • Another open-label, multicenter phase II study evaluated the efficacy and safety of CSF-1R inhibitor pimicotinib in cGVHD after ≥1 lines of systemic treatment (Abstract 99).

The following abstracts are also important studies to watch:

  • VAYHIT3: Exploratory interim results will be reported from this phase II study of ianalumab, an anti-B-cell–activating factor receptor, fully human, IgG1 monoclonal antibody, in patients with primary ITP previously treated with ≥2 lines of therapy (Abstract 710).
  • Agave-201: This secondary analysis of the Agave-201 trial evaluated the dynamics of overall and organ-specific responses to the FDA-approved agent axatilimab, an anti–CSF-1R IgG4 humanized monoclonal antibody, in patients with previously treated cGVHD who responded within the first 6 treatment cycles (Abstract 98).

Continue

Poll

1.

What topic being presented at ASH 2024 are you most interested in this year?

Submit